Cargando…

Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

BACKGROUND: There have been limited studies directly comparing the long-term efficacy between entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study was aimed to compare the long-term efficacy between them in treatment-naïve chronic hepatitis B (CHB). METHODS: Out of 345 CHB patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ji Won, Kwak, Kyeong Min, Kim, Sung Eun, Jang, Myoung Kuk, Suk, Ki Tae, Kim, Dong Joon, Park, Sang Hoon, Lee, Myung Seok, Kim, Hyoung Su, Park, Choong Kee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345200/
https://www.ncbi.nlm.nih.gov/pubmed/28279168
http://dx.doi.org/10.1186/s12876-017-0596-7
_version_ 1782513670873415680
author Park, Ji Won
Kwak, Kyeong Min
Kim, Sung Eun
Jang, Myoung Kuk
Suk, Ki Tae
Kim, Dong Joon
Park, Sang Hoon
Lee, Myung Seok
Kim, Hyoung Su
Park, Choong Kee
author_facet Park, Ji Won
Kwak, Kyeong Min
Kim, Sung Eun
Jang, Myoung Kuk
Suk, Ki Tae
Kim, Dong Joon
Park, Sang Hoon
Lee, Myung Seok
Kim, Hyoung Su
Park, Choong Kee
author_sort Park, Ji Won
collection PubMed
description BACKGROUND: There have been limited studies directly comparing the long-term efficacy between entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study was aimed to compare the long-term efficacy between them in treatment-naïve chronic hepatitis B (CHB). METHODS: Out of 345 CHB patients who received first line therapy with ETV (n = 200) or TDF (n = 145) in a cohort, 210 patients were analyzed using propensity score matching, at a ratio of 1:1. RESULTS: Two groups showed no difference in baseline characteristics. During the follow-up of 12 months, HBV DNA levels were similarly suppressed in both groups (ETV vs. TDF; −5.01 vs. -5.242 log(10)IU/mL, P = 0.559). At month 12, both groups showed no difference in terms of the serologic, biochemical and virologic (VR) response. In multivariate analysis, the initial virologic response at 3 months (IVR-3) was independent factor for VR at 1 year. During the long-term follow-up, HBV DNA levels were more strongly suppressed by TDF than ETV in hepatitis B e antigen (HBeAg) positive patients (P = 0.035), especially with high viral load (P = 0.012), although there was no significant difference in overall VR between two groups. The type of antivirals was not an independent factor for long-term VR. CONCLUSIONS: Although either ETV or TDF, overall, may show a comparable long-term antiviral efficacy in treatment-naïve CHB, TDF might be better regimen than ETV in the subgroup of HBeAg-positive CHB, especially with a higher HBV DNA levels.
format Online
Article
Text
id pubmed-5345200
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53452002017-03-14 Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients Park, Ji Won Kwak, Kyeong Min Kim, Sung Eun Jang, Myoung Kuk Suk, Ki Tae Kim, Dong Joon Park, Sang Hoon Lee, Myung Seok Kim, Hyoung Su Park, Choong Kee BMC Gastroenterol Research Article BACKGROUND: There have been limited studies directly comparing the long-term efficacy between entecavir (ETV) and tenofovir disoproxil fumarate (TDF). This study was aimed to compare the long-term efficacy between them in treatment-naïve chronic hepatitis B (CHB). METHODS: Out of 345 CHB patients who received first line therapy with ETV (n = 200) or TDF (n = 145) in a cohort, 210 patients were analyzed using propensity score matching, at a ratio of 1:1. RESULTS: Two groups showed no difference in baseline characteristics. During the follow-up of 12 months, HBV DNA levels were similarly suppressed in both groups (ETV vs. TDF; −5.01 vs. -5.242 log(10)IU/mL, P = 0.559). At month 12, both groups showed no difference in terms of the serologic, biochemical and virologic (VR) response. In multivariate analysis, the initial virologic response at 3 months (IVR-3) was independent factor for VR at 1 year. During the long-term follow-up, HBV DNA levels were more strongly suppressed by TDF than ETV in hepatitis B e antigen (HBeAg) positive patients (P = 0.035), especially with high viral load (P = 0.012), although there was no significant difference in overall VR between two groups. The type of antivirals was not an independent factor for long-term VR. CONCLUSIONS: Although either ETV or TDF, overall, may show a comparable long-term antiviral efficacy in treatment-naïve CHB, TDF might be better regimen than ETV in the subgroup of HBeAg-positive CHB, especially with a higher HBV DNA levels. BioMed Central 2017-03-09 /pmc/articles/PMC5345200/ /pubmed/28279168 http://dx.doi.org/10.1186/s12876-017-0596-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Park, Ji Won
Kwak, Kyeong Min
Kim, Sung Eun
Jang, Myoung Kuk
Suk, Ki Tae
Kim, Dong Joon
Park, Sang Hoon
Lee, Myung Seok
Kim, Hyoung Su
Park, Choong Kee
Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
title Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
title_full Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
title_fullStr Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
title_full_unstemmed Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
title_short Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
title_sort comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis b patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345200/
https://www.ncbi.nlm.nih.gov/pubmed/28279168
http://dx.doi.org/10.1186/s12876-017-0596-7
work_keys_str_mv AT parkjiwon comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients
AT kwakkyeongmin comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients
AT kimsungeun comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients
AT jangmyoungkuk comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients
AT sukkitae comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients
AT kimdongjoon comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients
AT parksanghoon comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients
AT leemyungseok comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients
AT kimhyoungsu comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients
AT parkchoongkee comparisonofthelongtermefficacybetweenentecavirandtenofovirintreatmentnaivechronichepatitisbpatients